Biophage Pharma
1995
FOUNDED
M&A
STATUS
M&A
LATEST DEAL TYPE
2
FINANCING ROUNDS
Description
Developer of phage-based biotechnology product. The company is focused on the development of phage-based technologies for the detection and management of pathogenic bacteria. It operates two divisions: a therapeutic division involved in the management of bacterial contaminations in the medical, veterinary and environmental; and a biosensors division dedicated to the development and commercialization of novel biosensors.
Formerly Known As
Almont Capital
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Other Pharmaceuticals and Biotechnology
Acquirer
Phagelux Canada
Primary Office
- 6100 Royalmount
- Montreal, Quebec H4P 2R2
- Canada
Biophage Pharma Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Biophage Pharma‘s full profile, request access.
Request full access to PitchBookBiophage Pharma Executive Team (4)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Theodore Rousseau | Chief Executive Officer |
3 Former Executives
You’re viewing 1 of 4 executives. Get the full list »